Riamilovir, sold under the brand name Triazavirin, is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical.

It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity.

No experimental biochemical studies on the activity of riamilovir relating to SARS-CoV-2 or influenza target proteins have so far been published.

[27] Randomized, double-blind, multicenter trial published in 2024 show that Riamilovir has demonstrated efficacy in both treating and preventing COVID-19.

[28][29] In August 2014, the Ministry of Health of Russia issued a registration certificate for riamilovir (Triazavirin).